Background: Liquid biopsy is the new non-invasive technology to explore the molecular profile. We evaluate molecular alteration from matched tissue and liquid specimen in NSCLC patients using NGS. Method: A total 61 matched tumors and cfDNA in NSCLC patients were retrieved for DNA extraction. All qualified samples were analyzed by using Next Generation Sequencing (NGS) with Gene read Qiagen Lung Cancer Panel sequencing 45 Genes on Ion Torrent system.Variants from NGS with coverage of higher than 1000X of tissues and 10000X of liquid biopsy, cutoff at 3% variant frequency were considered positive. Each detected mutation was validated by the different method. EGFRmutation detected at this cutoff was validated by Real-time PCR technique using the ARMS-PCR (Amoy DX Kit) for tissue samples and droplet-digital PCR (ddPCR) for blood samples in all samples. Result: This study found 59.0% and 19.7% of EGFR mutation, 14.75% and 8.20% of KRAS mutation in tissues and cfDNA, respectively. Moreover, we found 3.29% of BRAF V600E, 1.64% of MET exon14 splice site, and 1.64% of ROS1 mutation in tissue NGS and also confirmed by the other techniques, but there was none of these mutations in the blood sample. Looking at EGFR-mutation detected by different techniques, higher sensitivity, specificity, positive-predictive value, negative-predictive values, and concordant rate were found in tissue NGS and liquid ddPCR compared with liquid NGS at cutoff 3% of variant frequency detection, when the gold standard for validation was ARMS-PCR in tissue testing (Table1). Conclusion: Using tissue for molecular profile testing is still being the gold standard testing. Liquid biopsy is less invasive, but in our study, liquid NGS performed less sensitivity, specificity, PPV, NPV, and concordance rate compared with tissue NGS. We need to explore more for proper cutoff of variant allele frequency to develop more sensitivity and specificity of liquid NGS.
P3.09-20 A Simple and Versatile Next-Generation Sequencing Technology for Co-Detection of RNA Structural Variants and DNA Mutations in Lung Cancer H. Zhu, S. Gokul, G. Latham Research and Development, Asuragen Inc., Austin/US Background: Variants associated with non-small cell lung cancer (NSCLC) initiation and progression include DNA mutations, copy number variants, RNA fusions and splicing isoforms. Co-detection of DNA and RNA variants has become increasingly important to shorten time from samples to results and optimize personalized medicine for NSCLC. Here we describe the unification of next-generation sequencing (NGS) workflows using library pooling to reliably and sensitively quantify both DNA and RNA variants from tumor FFPE nucleic acids. Method: Total nucleic acid (TNA) and DNA were isolated from residual FFPE NSCLC biopsies and cancer cell lines. The QuantideX ® NGS RNA Lung Cancer Kit (RUO, Asuragen) and QuantideX ® NGS DNA Hotspot 21 Kit (Prototype, Asuragen) were evaluated on the MiSeq ® System. DNA and RNA libraries were sequenced on a single MiSeq flow cell. Multiple library pooling strategies were assessed to provide workflow flexibility. All data was analyzed using QuantideX ® NGS Reporter 3.0 software. Result: The average time from sample QC to MiSeq loading was 10 hours. Including 40-hour instrument run time and data processing and analysis, the sample-to-answer time was less than three days. Library pooling experiments evaluated sample run capacity, coverage Background: Lung cancer is staged according to TNM classification, which encodes the anatomic extent of the disease. This is the most important prognostic factor in patients diagnosed with lung cancer. CT scan is a basic imaging modality used for pre-treatment tumour staging (T staging). Each centimetre increase in size leads to worsening of prognosis. Adjuvant treatment decisions are based upon the final histopathological tumour size. Accurate clinical and pathologic correlation has been an important focus of research in many cancers. The objective of our study is to see for any discordance with respect to tumour size calculated by CT scan and final histopathological specimen in patients of carcinoma lung undergoing upfront surgery. Method: All patients of lung cancer operated upfront between 2012 to 2017 were included in the study. Any patient with chest wall involvement, significant pleural effusion and tumours of main bronchus were excluded. CT scans were acquired from the supraclavicular region through the adrenal glands using a 1.25 mm slice thickness with 1.25 mm spacing following deep inspiration. Based on tumour perimeter maximum tumour size was calculated. The largest diameter of resected lung tumour was recorded using a standard ruler by the pathologist. A mean, median and range for both the CT diameter and pathology diameter were obtained. A paired t-test was used to examine the measurement difference between CT and pathology. Result: A total of 109 patients were included in the study. Most common histology was Squamous cell carcinoma (n¼40,36%), followed by Adenocarcinoma (n¼32,29.3%), Neuroendocrine tumour(n¼27,24.77%) and other histologies (n¼10,9.17%). Among these patients, 22 tumours were located in right upper lobe (20.18%), 10: right middle lobe (9.17%), 25:right lower lobe(22.93%), 31: left upper lobe(28.44%) and 21: left lower lobe(19.26%). The mean size of tumour on CT scan is 4.92cm (SD¼1.852cm, range:1-10 cm) and mean size on grossing is 4.5cm(SD¼1.774cm,range:0.5-9.5cm)(p<0.05). The difference between the CT diameter and histopathological size is statistically significant. Tumour location and histology did not add any difference to tumour shrinkage. Conclusion: Our study demonstrates that there is a statistically significant difference between tumour diameter as measured by CT and its pathologic size. These differences could have implications in the treatment and prognosis of patients with lung cancer. Keywords: Pathology, lung cancer, imaging However, methods such as the transbronchial biopsy and the computed tomography-guided fine-needle aspiration cytology are limited in their ability to diagnose such small lung tumors. We evaluated about the association of the cytological features with the histological examination using the surgically resected specimen. Method: 169 patients, age between 31e87 years old, who showed radiological signs of peripheral lung tumors less than 3.0cm in diameter on CT images, underwent surgical resection at our institution between 2015 and 2016. The histological examination was performed on surgical specimen, fixed with 10% formalin and stain with HematoxylineEosin. The cytological examination was performed on stamps from surgical material by Papanicolaou staining. The morphological features were compared both histopathogical diagnosis and cytological diagnosis of imprint cyotology derived from the resected specimen. Interobserver reproducibility was assessed by Kappa coefficient providing a measure for agreement beyond chance. Result: By histological examination (in the 169 cases), the diagnostic of lung cancer was given with the establishing of the histological type. In 139 cases (82.2%) of the cases diagnosed as adenocarcinoma, in 25 cases (14.8%) squamous cell carcinoma, in 3cases (1.7%) was neuroendocrine tumors, and one case each of adenosquamous carcinoma and pleomorphic carcinoma. There was 86.3% (146 of 169 cases) agreement with a k statisticvalue of 0.65. Obtained kappa values from imprint cytology showed good (from 0.60 to 0.8) for detection of epithelial cell abnormalities indicating high observer diagnostic reproducibility. Conclusion: This kappa statistic method allows assessment of the diagnostic quality of a respiratory cytology. Imprint cytology for small peripheral lung cancer is a useful method for evaluating tumors. Our data indicate the fact that the cytological
